Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Condition(s) targeted: Bronchiolitis

Intervention: Inhaled Furosemide vs Placebo (Normal Saline) (Drug)

Phase: Phase 1

Status: Not yet recruiting

Sponsored by: Bnai Zion Medical Center

Official(s) and/or principal investigator(s):
Amir Kugelman, Principal Investigator, Affiliation: Bnai Zion Medical Center

Overall contact:
Amir Kugelman, MD, Phone: 972-4-8345397, Email: dramir@netvision.net.il

We hypothesize that inhaled Furosemide will be an effective treatment in infants with acute bronchiolitis.

Official title: Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Clinical respiratory effects

Secondary outcome:

1. The duration of hospitalization

2. Time weaned off oxygen

3. Time to full enteral feeding

Minimum age: N/A. Maximum age: 12 Months. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age: 0-12 months.

- Infants who are otherwise healthy

- Infants with chronic lung disease of prematurity (BPD) will be included, but will be

analyzed separately.

- Parents signed a written informed consent.

Exclusion Criteria:

- • Other previous or co-morbidity, specifically: respiratory (other than BPD, like

Asthma or Cystic Fibrosis), cardiac or renal disease or anomaly.

Amir Kugelman, MD, Phone: 972-4-8345397, Email: dramir@netvision.net.il

Bnai Zion Medical Center and Naharia Galilli Medical Center, Haifa 31048, Israel

Starting date: December 2005
Ending date: April 2006
Last updated: December 5, 2005